Therapy News and Research

RSS

Experimental cure for Type 1 diabetes

Researchers have developed an experimental cure for Type 1 diabetes, a disease that affects about one in every 400 to 600 children and adolescents. They will present their results in a mouse model of Type 1 diabetes on Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Boston Scientific Corporation today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation System, including balloon lengths of 120 and 150 mm. The PolarCath System is used to restore blood flow in patients with critical limb ischemia (severe blockages in the arteries below the knee) and blockages in the femoral and popliteal (behind the knee) arteries. Both conditions result from peripheral artery disease.

21 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company today announced that LIVALO® (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug Administration (FDA) in August 2009 is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed dyslipidemia. LIVALO is available in doses of 1 mg, 2 mg and 4 mg.

21 Jun 2010

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

21 Jun 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, was presented yesterday at the 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which is held through June 22, 2010 at the San Diego Convention Center in San Diego, California.

21 Jun 2010

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Recently, oral cancer survivor Jeanna Richelson, organized the first Chattanooga Oral Cancer Awareness Walk, which raised donations for the Oral Cancer Foundation, and much needed awareness of a disease that too few Americans know about. According to the foundation's executive director Brian Hill, "I don't believe there has ever been an oral cancer walk that was this successful in its first year. This was an absolutely amazing effort by Jeanna and those who helped her make this possible."

21 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

FDA accepts ev3's Pipeline Embolization Device PMA for expedited review

ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.

21 Jun 2010

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites.

21 Jun 2010

Medco Health Solutions, Celesio join to help relieve financial burden on healthcare payors across Europe

Medco Health Solutions, Inc. and Celesio AG, two of the world's leading pharmacy-driven healthcare companies, today announced a joint venture with a long-term goal of improving patient health and helping to relieve the crushing financial burden on healthcare payors across Europe.

21 Jun 2010

GSK acquires exclusive marketing rights for new topical patch from Labtec GmbH

In a recently finalized license agreement, the Consumer Healthcare division of GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec GmbH, the transdermal and topical patch specialist based in Langenfeld, Germany. The agreement designates Labtec as the exclusive manufacturer.

21 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

21 Jun 2010

Too much tea raises the risk of rheumatoid arthritis: Study

Rheumatoid arthritis (RA) a severely debilitating inflammatory disease of the joints is on the rise worldwide. It leads to severe pain, stiffness, swelling and loss of movement of joints like knees, wrist and even fingers. RA affects women more than men. RA occurs in people who develop a rogue immune system that attacks the tissue that lines the joint cavities called the synovium leading to degeneration of the joints and the symptoms of the disease. In 1995 36.4 per 100,000 women were diagnosed with RA whereas in 2005 the number rose to 54 per 100,000 women.

20 Jun 2010

Special Olympics Minnesota's 2010 Summer Games conclude

Today is the last day of competition at the Special Olympics Minnesota's 2010 Summer Games. Volleyball competition will take place on the third floor of the University of Minnesota's Recreation Center (1906 University Avenue SE) from 9 a.m. to 4 p.m. and tennis competition will be held at Life Time Fitness in Lakeville (18425 Dodd Boulevard) from 9 a.m.-1 p.m. In addition, artistic gymnastics competition will start at 2 p.m. and conclude at 5:30 p.m. at Mini-Hops Gymnastics Club in Minnetonka (131 Cheshire Lane, Suite 100).

19 Jun 2010

End Duchenne Day to be celebrated on June 26, 2010: PPMD

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy, announced that the Mayor of Denver, Colorado, John W. Hickenlooper, has proclaimed June 26, 2010 "End Duchenne Day" in recognition of PPMD's 16th Annual Connect Conference. Denver is playing host to the country's largest Duchenne-specific, international conference, June 24 – 27, 2010.

19 Jun 2010

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

NewYork-Presbyterian/Columbia announces recruitment for clinical trial of robotic devices for stroke survivors

As many as half of stroke survivors lose some of their ability to move their extremities. Now specialists in rehabilitation medicine at NewYork-Presbyterian Hospital/Columbia University Medical Center are pioneering the use of robotic devices to help them regain this function. Patients are currently being recruited for ongoing clinical research trials with the new devices.

19 Jun 2010

CureDuchenne kicks off national fundraiser Pick Your Peak

CureDuchenne, a national 501(c)3 dedicated to raising funds and awareness in the fight against Duchenne Muscular Dystrophy, is kicking off a national fundraiser Pick Your Peak. Outdoor enthusiasts, philanthropists, families of boys with DMD, and anyone excited to get out and climb for a cause will climb the peak of their choice on June 19-20, 2010.

19 Jun 2010

Therapy News and Research

Experimental cure for Type 1 diabetes

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

FDA accepts ev3's Pipeline Embolization Device PMA for expedited review

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Medco Health Solutions, Celesio join to help relieve financial burden on healthcare payors across Europe

GSK acquires exclusive marketing rights for new topical patch from Labtec GmbH

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

Too much tea raises the risk of rheumatoid arthritis: Study

Special Olympics Minnesota's 2010 Summer Games conclude

End Duchenne Day to be celebrated on June 26, 2010: PPMD

Active surveillance sufficient for patients with low-risk prostate cancer

NewYork-Presbyterian/Columbia announces recruitment for clinical trial of robotic devices for stroke survivors

CureDuchenne kicks off national fundraiser Pick Your Peak

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News